Nimbus Receives Additional Funding to Further Develop Protein Targets for Drug Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nimbus Discovery today announced an extension of its seed round of funding, which will be used to advance drug programs based on its in silco discovery platform.

The funding comes from Bill Gates and Richard Freisner, co-founder of chemical simulation software firm Schrödinger and a professor of chemistry at Columbia University. Atlas Venture, the founding investor in Nimbus, also was a participant.

Nimbus did not disclose the amount of the investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.